Article

Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias

2021-05-29

Abstract excerpt

The U.S. Food and Drug Administration (FDA) recently approved the treatment with pembrolizumab, an immune checkpoint inhibitor (ICI) targeting PD1 (anti-PD1), for patients with advanced solid tumors with a high tumor mutational burden (TMB) (defined as TMB ≥10 mutations/Mb). However, following recent studies suggest that TMB levels and response to ICI treatment may differ between male and female melanoma patients,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 77cb5fe0-dbc8-58c1-b2e1-792be0a3a841
DOI: 10.1101/2021.05.28.446208

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex biasDOI 10.1101/2021.05.28.446208Read

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.Semantic proximity Read

Sex-differential responses to immune checkpoint inhibitors across the disease continuum unified by tumor mutational burden.Semantic proximity Read

Sex-based mutational landscape confers sensitivity to checkpoint blockade immunotherapy in cutaneous melanomaSemantic proximity Read

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.Semantic proximity Read

The association between tumor mutational burden and prognosis is dependent on treatment context.Semantic proximity Read

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersSemantic proximity Read

Gender Disparity and Mutation Burden in Metastatic MelanomaSemantic proximity Read

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.Semantic proximity Read

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.Semantic proximity Read